Generex once again extends 8% convertible notes forbearance agreement to April 3

By Devika Patel

Knoxville, Tenn., March 27 - Generex Biotechnology Corp. once more extended a forbearance agreement with the holders of its 8% senior secured convertible notes to April 3, according to an 8-K filed Friday with the Securities and Exchange Commission.

According to the filing, the investors agreed on Feb. 27 to forbear from exercising their rights and remedies under the notes for a 21-day period ending March 20. That period has been extended twice to its current expiration.

Toronto-based Generex develops drug-delivery systems and technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.